저자의 연구 키워드

저자의 연구 키워드

#5-HT3 receptor antagonist

#가정의

#만족도

#암

#암성통증관리

#연명의료결정법

#윤리적 갈등

#의료기관윤리위원회

#인공호흡기

#임상윤리상담

#임상윤리자문

#임상윤리지원

#제도화

#지식

#태도

#통증

#호스피스·완화의료

#환자와 가족

#Acquired resistance

#Administration

#Advance care planning

#Age groups

#Anaplastic lymphoma kinase

#Anthracycline

#Antiemetics

#attitude

#Awareness

#Bevacizumab

#Blood platelets

#Brain death

#Breast neoplasms

#cancer

#cancer pain management

#cancer patients

#cancer patients and families

#Carcinoma

#Care

#CD56

#CD73

#Central nervous system

#Characteristics

#Chemoradiotherapy

#Chemotherapy

#Cisplatin

#clinical ethics consultant

#clinical ethics consultation

#clinical ethics support

#clinical practice guideline

#Clinical Trial

#Clinical trials

#Comorbidity

#Consensus guideline

#Cost analysis

#Costs and cost analysis

#Crizotinib

#Decision making

#De-escalation

#Definition

#Delivery of health care

#Diagrams.

#diffuse

#Diffuse large B-cell lymphoma

#Discussion

#Disease progression

#Disease-free survival

#Dolasetron mesylate

#Doxorubicin

#Drug-related side effects and adverse reactions

#EGFR C797S mutation

#EGFR kinase domain duplication

#EGFR mutation

#EGFR T790M mutation

#Elderly

#End-of-life

#End-of-life care

#Epidermal growth factor receptor

#ErbB receptors

#Erlotinib

#Esophageal neoplasms

#establishment

#ethical dilemma

#Evidence generation

#family medicine

#futile treatment

#Gastric Cancer

#G-CSF)

#Gefitinib

#Gemcitabine

#Genexol

#Germinoma

#Glioblastoma

#Glioma

#Granulocyte colony-stimulating factor

#Head and neck neoplasms

#Health care costs

#health care ethics committee

#health care survey

#Health expenditures

#Health technology assessment

#High-grade glioma

#Hospice

#hospice·palliative care

#Hospices

#hospital ethics committee

#Human papillomavirus

#Induction chemotherapy

#Infusion-related reaction

#Insurance coverage

#Interleukin-1beta

#Interstitial lung diseases

#Investigator-initiated trials

#Irinotecan

#knowledge

#Korean Cancer Study Group

#KRAS

#large B-cell

#legislation on life-sustaining treatment

#Leukocytes

#Life support care

#Life-sustaining treatment

#Lung injury

#Lung neoplasms

#Lymphoma

#Lymphoproliferative disorder

#mechanical ventilator

#Meta-analysis

#Methotrexate

#Nasal cavity

#Nasopharyngeal carcinoma

#Natural killer cells

#Nausea

#Neoplasms

#Neoplasms/drug therapy

#Neutropenia

#Next generation sequencing

#Nivolumab

#Nomograms

#Non?small cell lung carcinoma

#Non-small cell lung carcinoma

#Non–small cell lung carcinoma

#Non-small cell lung neoplasm

#non-small-cell lung

#Non-small-cell lung carcinoma

#Oncogenes

#Ondansetron

#OPB-31121

#Oral

#Orbit evisceration

#Overall survival

#Paclitaxel

#pain

#Palliative

#palliative care

#Paranasal sinuses

#Patient-Centered Clinical Research Coordinating Center (PACEN)

#Patients

#Pemetrexed

#Perception

#P-glycoprotein

#Pharmacokinetics

#Phase 1

#Phase I

#Phase II clinical trial

#Platinum

#Pneumocystis pneumonia

#Pneumonia

#Policy

#polypharmacy

#Positron emission tomography computed tomography

#potential drug interaction

#Precision medicine

#Prevention

#Prognosis

#Prognostic factor

#Proportional hazards models

#Protein kinase inhibitors

#Quality standard

#Radiation

#Radiation toxicity

#Radiation-induced neoplasms

#Radical radiotherapy

#Radiotherapy

#RAND method

#Resistance

#Response Evaluation Criteria in Solid Tumors

#Resuscitation orders

#Review

#Rituximab

#satisfaction

#Sensitivity and specificity

#Skin

#Small cell lung carcinoma

#Solid tumor

#Squamous cell carcinoma of tonsil

#STAT3

#STAT3 inhibitor

#Study designs

#Survival

#Survival analysis

#Targeted agents

#Targeted molecular therapy

#Taxane

#Terminal

#Terminal cancer

#terminal care

#Terminally ill

#the Life- Sustaining Treatment Decision-Making Act

#Thromboembolism

#Transforming growth factor beta1

#Treatment outcome

#Trend

#Tumor size

#Tyrosine kinase inhibitor

#Vascular endothelial growth factor

#Vinorelbine

#Volition

#Vomiting